Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Treatment Monitoring, Adherence, and Persistence (1 of 3)
The evidence to date has not clarified the value of BMD monitoring to assess treatment effectiveness. According to indirect evidence, even patients who continue to lose BMD during therapy experience statistically and clinically significant reductions in fracture risk. The strength of evidence in support of this conclusion is high.
One large randomized controlled trial (RCT) showed that after five years of initial alendronate therapy, an additional five years of therapy continued to reduce vertebral fracture risk. Continued reduction in nonvertebral fracture risk was found at 10 years (in post-hoc analysis) only in women who after five years of treatment had osteoporosis (T-scores less than -2.5) or prevalent vertebral fractures. The strength of evidence in support of this finding is moderate.
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | bone mineral density | BMD | antifracture | alendronate | vertebral | nonvertebral
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.